(NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the fourth quarter and year ended December 31, ...

Adjusted Funds From Operations ("AFFO”) 1 was $78.3 million 2, or $0.34 per share, in fourth quarter 2024, compared to $71.7 ...